



## 9 Abstract

10 Three extraction methods were sequentially combined to obtain fractions from  
11 *Lentinula edodes* (shiitake mushrooms) containing bioactive compounds against  
12 cardiovascular diseases (CVDs). Fruiting bodies were first extracted with plain water,  
13 obtained residue was then submitted to supercritical fluid extraction (SFE) and remaining  
14 residue submitted to hot water extraction. Sequential design allowed re-utilization of the non-  
15 extracted material as raw material for the successive extractions increasing extraction yields  
16 and separating interesting compounds. Obtained fractions contained different amounts of  $\beta$ -  
17 glucans, chitins, eritadenine, lenthionine, ergosterol, proteins/peptides and phenolic  
18 compounds conferring them different bioactivities. Water soluble fractions showed high  
19 antioxidant activities (ABTS<sup>+</sup>• and DPPH• scavenging capacity and reducing power), they  
20 were also able to inhibit one of the main enzymes involved in hypertension (angiotensin-I  
21 converting enzyme) and the key enzyme of cholesterol metabolism (3-hydroxy-3-  
22 methylglutaryl coenzyme A reductase). The latter inhibitory activity was also noticed in SFE  
23 extracts although ergosterol and other lipid-like molecules were isolated. Dietary fibers were  
24 separated in the third extraction. Therefore, with this sequential extraction procedure  
25 bioactive compounds against CVDs can be selectively separated from a single batch of  
26 shiitake powder.

27 **Keywords:** Supercritical CO<sub>2</sub> extraction; Shiitake mushrooms; Cholesterol; Antioxidant  
28 activity, HMGCR inhibition.

30 Cardiovascular diseases (CVDs) are still one of the leading causes of mortality in  
31 developed countries. CVDs are associated with multiple factors such as high triglycerides  
32 and low density lipoprotein cholesterol (LDLc) levels, LDL oxidation, increased platelet  
33 aggregation, hypertension and smoking.<sup>1,2</sup>

34 Nowadays, functional foods containing phytosterols or  $\beta$ -glucans are being  
35 commercialized to reduce low to moderate hypercholesterolemia because these compounds  
36 showed the ability of impairing exogenous cholesterol absorption. Hypotensive foods are  
37 also marketed containing specific peptides able to inhibit the angiotensin I converting enzyme  
38 (ACE)<sup>3</sup> and many juices and functional drinks indicate that they contain many compounds  
39 with high antioxidant properties. These compounds might inhibit LDL oxidation, prevent  
40 atheroma plaque formation etc. contributing to reduce the risk of CVDs. However, a more  
41 effective novel food may be designed if all compounds are combined and, besides those  
42 inhibiting cholesterol absorption, other compounds are incorporated such as those reducing  
43 the risk of CVDs by different mechanisms of action.<sup>4</sup>

44 Edible mushrooms are natural sources of hypocholesterolemic compounds, such as  
45 fungal sterols (ergosterol and derivatives) and polysaccharides ( $\beta$ -glucans, chitins, etc.) that  
46 according to *in vitro* experiments might inhibit cholesterol absorption and biosynthesis.<sup>4-7</sup>  
47 Eritadenine (2(R),3(R)-dihydroxy-4-(9-adenyl) butanoic acid) from *Lentinula edodes*  
48 (shiitake mushrooms) was also able to lower cholesterol levels by acting as an inhibitor of  
49 the S-adenosyl-L-homocysteine hydrolase involved in the hepatic phospholipid  
50 metabolism.<sup>8,9</sup> When lard was supplemented with extracts containing these compounds and  
51 fed to mice, they succeeded to avoid the increasing of cholesterol levels noticed in control  
52 mice fed only with lard.<sup>10</sup>

53 Moreover, water extracts obtained from edible mushrooms such as *Hypsizygos*  
54 *marmoreus* and *Lactarius camphorates* were also able to inhibit ACE because of their  
55 hypotensive peptides<sup>11,12</sup> and lenthionine (1,2,3,5,6-pentahiepane), an organosulfur  
56 compound responsible for the characteristic flavor of shiitake mushrooms, inhibited platelet  
57 aggregation<sup>13</sup>. Water and hot water extracts from other mushroom species also showed  
58 interesting antioxidant activities that correlated to their levels of ergothioneine and phenolic  
59 compounds.<sup>14-16</sup>

60 Several methods to isolate or extract each type of those previously mentioned compounds  
61 have been already reported. Different  $\beta$ -glucans types are usually isolated by alkali/acid  
62 treatments, hot water (120 °C, 20 min), microwave, pressurized solvent or ultrasound assisted  
63 extractions,<sup>17-19</sup> chitins needed more drastic treatments<sup>20</sup> and sterols were isolated by using  
64 mixtures of organic solvents or supercritical CO<sub>2</sub> extractions.<sup>21</sup> However, all these methods  
65 were optimized to use mushrooms as raw material and for each extraction, a new batch of  
66 powdered mushrooms should be used. In the present work, a sequential extraction method  
67 was designed to extract from the same batch of mushroom powder a few fractions enriched  
68 in different bioactive compounds against CVDs. The residue remaining after one extraction  
69 was used to extract other compounds at the following extraction step instead of using  
70 different batches of mushroom powder for each type of compound.

## 71 **Materials and Methods**

### 72 ***Biological material***

73 Dry *Lentinula edodes* S. (Berkeley) mushrooms were obtained in a local market  
74 (Madrid, Spain). Fruiting bodies were ground as a whole or divided into caps and stipes until  
75 a fine powder was obtained and stored at -20 °C as indicated by Ramirez-Anguiano *et al.*,  
76 2007<sup>16</sup> (they were used to analyze separated tissues). Larger amounts of powdered shiitake

77 mushrooms were also purchased from Glucanfeed S.L. (La Rioja, Spain). Obtained powder  
78 showed a particle size lower than 0.5 mm, and moisture content lower than 5% and it was  
79 stored in darkness at -20 °C until further use.

## 80 ***Reagents***

81 Solvents as hexane (95%), chloroform (HPLC grade), methanol (HPLC grade),  
82 acetonitrile (HPLC grade) were obtained from LAB-SCAN (Gliwice, Poland) and absolute  
83 ethanol, sodium carbonate (Na<sub>2</sub>CO<sub>3</sub>) and sulfuric acid (H<sub>2</sub>SO<sub>4</sub>) from Panreac (Barcelona,  
84 Spain). Potassium hydroxide (KOH), ascorbic acid, 2,6-Di-tert-butyl-*p*-cresol (BHT), bovine  
85 serum albumin (BSA), acetylacetone, *p*-dimethylaminebenzaldehyde, Trizma base, HCl  
86 (37%), trifluoroacetic acid (99%), phenol, Folin Ciocalteu's phenol reagent, 2,2'-azino-bis(3-  
87 ethylbenzothiazoline-6-sulphonic acid) (ABTS), potassium persulfate, Angiotensin-I  
88 Converting Enzyme (ACE) (5 UN/mL), zinc chloride (ZnCl<sub>2</sub>) solution (0.1 M) as well as  
89 hexadecane, ergosterol (95%), D-glucose, D-glucosamine hydrochloride, gallic acid, 2,2-  
90 diphenyl-1-picrylhydrazyl (DPPH), sodium phosphate dibasis dihydrate (NaH<sub>2</sub>PO<sub>4</sub> · 2H<sub>2</sub>O),  
91 sodium phosphate monobasic sodium phosphate dibasic anhydrous (Na<sub>2</sub>HPO<sub>4</sub>), potassium  
92 ferricyanide (K<sub>3</sub>[Fe(CN)<sub>6</sub>]), ferric chloride (FeCl<sub>3</sub>) and Trolox were purchased from Sigma-  
93 Aldrich Quimica (Madrid, Spain). CO<sub>2</sub> was supplied by Air-Liquid, S.A. (Madrid, Spain). D-  
94 Eritadenine (90%) was acquired from Sy Synchem UG & Co. KG (Felsberg, Germany),  
95 lenthionine (80%) from Cymit (Barcelona, Spain) and N-(2-aminobenzoyl)glycyl-4-nitro-1-  
96 phenylalaninyl-1-proline (Abz-Gly-Phe(NO<sub>2</sub>)-Pro) from Bachem Feinchemikalien (Bubendorf,  
97 Switzerland). All other reagents and solvents were used of analytical grade.

## 98 ***Sequential extractions***

99 A method to obtain different bioactive fractions from powdered shiitake mushrooms  
100 was optimized based on three successive extractions (Figure 1). Firstly (Step A), mushroom

101 powder was mixed with water (50 g/L) at room temperature (RT) and vigorously stirred  
102 during 1 minute. Afterwards, the mixture was centrifuged (7 min, 7000 rpm, 10°C) in a  
103 Heraus Multifuge 3SR+ centrifuge (Thermo Fisher Scientific, Madrid, Spain). Obtained  
104 supernatant (considered extract ExA) was separated from the residue (ReA) and both  
105 fractions were freeze dried in a LyoBeta 15 lyophilizer (Telstar, Madrid, Spain).

106 Secondly (Step B), freeze-dried ReA (253 g) was ground, sieved until particles size  
107 < 0.5 mm and submitted to supercritical fluid extraction (SFE). ReA was mixed with 1.9 kg  
108 of 5 mm diameter stainless steel spheres (a ratio 1:1 (v/v) extract:spheres) in a 2L extraction  
109 cell connected to a SFE pilot-scale plant (model SF2000, TharTechnology, Pittsburgh, PA,  
110 USA). Pressurized CO<sub>2</sub> was forced to reach supercritical state and injected in the loaded  
111 extraction cell. Extracted material was collected in two different separators (S1 and S2) each  
112 of 0.5 L capacity with independent control of temperature and pressure. The extraction vessel  
113 had a ratio of 5.5 height/diameter (a detailed explanation of the experimental device can be  
114 found at Garcia-Risco *et al.*, 2011<sup>22</sup>). Extraction was carried out at 35 MPa and 40 °C.  
115 Pressure of S1 and S2 was maintained at 10 and 6 MPa respectively and temperature in both  
116 of them was 40 °C. The CO<sub>2</sub> flow was set at 3.6 kg/h and during the total extraction time (3  
117 h) and it was recirculated. Extracted compounds were precipitated in both separators and at  
118 the end of the extraction process, the fractions were dragged with ethanol and immediately  
119 submitted to concentration until dryness on a rotary vacuum evaporator. Dried extract (ExB)  
120 was stored at -20°C until further analysis and non-extracted residual material (ReB) was  
121 separated from steel spheres by sieving.

122 Finally (Step C), ReB (100 g/L) was submitted to hot water extraction (98 °C) in a  
123 0.5 L flask during 1 hour under vigorous stirring and reflux using a glass steam condenser.  
124 The soluble (ExC) and non-soluble (ReC) fractions were separated by centrifugation (7 min,  
125 7000 rpm, 10 °C) and freeze dried.

## 126 ***Carbohydrates determinations***

127           The total carbohydrate content of shiitake mushroom samples or obtained extracts  
128 was determined by the phenol-sulphuric acid method adapted from Dubois *et al.* (1956).<sup>23</sup>  
129 Briefly, samples (1 mg) were mixed with 1 mL of MilliQ water and stirred during 2 min. The  
130 mixtures (25  $\mu$ L) were added to a 96-well plate, plus 25  $\mu$ L of 5% phenol solution (w/v) and  
131 125  $\mu$ L of concentrated H<sub>2</sub>SO<sub>4</sub>. Afterwards, the plate was sealed and incubated in a water  
132 bath at 80 °C for 30 min. Samples absorbance was read using a M200 Plate Reader (Tecan,  
133 Mannedorf, Switzerland) at 595 nm. A standard curve of D-glucose (0.032 to 0.8 mg/mL)  
134 was used for quantification.

135           Chitin content was determined according to Smiderle *et al.* (2017).<sup>18</sup> Firstly, samples  
136 were hydrolyzed with 6 M HCl at 100 °C for 2 h and adjusted to pH 10.0 after cooling down.  
137 Then, hydrolyzed samples (250  $\mu$ L) were treated as described by Rementería *et al.* (1991).<sup>24</sup>  
138 Samples absorbance was measured at 530 nm using an Evolution 600 UV-vis (Thermo Fisher  
139 Scientific, Spain) spectrophotometer. A glucosamine hydrochloride standard curve was used  
140 for quantification.

141           The  $\beta$ -glucan content of the obtained mushroom samples and extracts (50 mg) was  
142 evaluated by a  $\beta$ -glucan determination kit specific for mushrooms and yeasts (Megazyme®,  
143 Biocom, Barcelona, Spain) following the instructions of the user's manual.

## 144 ***Total phenol content and proteins or peptides determination***

145           The total phenol concentration of samples (10 mg) was determined by the Folin-  
146 Ciocalteu method according to the procedure of Ramirez-Anguiano *et al.* (2007).<sup>16</sup> Gallic  
147 acid was used as standard for quantification.

148           The total protein concentration of the samples (10 mg/mL) was determined using the  
149 Bradford method reagents (Sigma-Aldrich, Madrid, Spain) according to the Instruction  
150 Manual. To determine the amount of peptides, extracts were solubilized in water (100  
151 mg/mL) and submitted to centrifugation (14000 rpm, 30 min) using Amicon Ultra filter  
152 devices with Ultracel 3K membrane (Millipore, Billerica, USA) obtaining a filtrate (< 3 kDa)  
153 and a concentrate (> 3 kDa). The latter fraction was submitted to a second centrifugation  
154 (14000 rpm, 20 min) using Nanosep centrifugal devices with Omega 10K membrane (Pall  
155 Life Sciences, New York, USA), obtaining a filtrate (fraction with MW between 3 and 10  
156 kDa) and a concentrate (> 10 kDa). The obtained fractions were freeze dried and mixed with  
157 the Bradford reagent as described above. BSA was used as standard (0.0125 to 0.5 mg/mL)  
158 for protein quantification.

#### 159 ***Eritadenine and lenthionine determination by HPLC-DAD***

160           Eritadenine was extracted from the samples and analyzed following the procedure of  
161 Afrin *et al.* (2016)<sup>25</sup> with modifications. Briefly, samples (1 g) were mixed with 10 mL of  
162 60% ethanol (v/v) and stirred for 2 min. The mixture was centrifugated (15 min, 7000 rpm,  
163 10 °C) and the supernatant was collected. Afterwards, 10 mL of 60% ethanol (v/v) was added  
164 for a second extraction and both supernatants were pooled together and submitted to vacuum  
165 filtration. The filtrate was concentrated on a rotary vacuum extractor at 60 °C until dryness.  
166 Identification and quantification of eritadenine were carried out using a C18 Spherisorb  
167 ODS2 4 x 250 mm analytical column with a 5 µm particle size (Waters, Missisagua, Ontario,  
168 Canada) coupled to an HPLC system (Pro-Star 330, Varian, Madrid, Spain) with PDA  
169 detector (Pro-Star 363 module, Varian, Madrid, Spain). Samples were dissolved in mobile  
170 phase (5 mg/mL) and they were injected (10 µL) and developed under a constant flow (0.5  
171 mL/min) and an isocratic mobile phase of water:acetonitrile (98:2, v/v 1% TFA). Eritadenine

172 was quantified at 260 nm using a commercial standard. The compound eluted at 11.6 min  
173 and showed the characteristic eritadenine UV-spectrum.

174 Lenthionine determination was carried out according to the procedure of Hiraide *et*  
175 *al.* (2010)<sup>26</sup> with slight modifications. Basically, samples (50 mg) were mixed with 1 mL of  
176 0.2 M Tris-HCl buffer (pH 8.0) and stirred for 1 h. Afterwards, methanol (0.5 mL) was added,  
177 stirred for 2 min and centrifuged (14000 rpm 5 min). The obtained supernatant was collected  
178 and the residue submitted to extraction twice. Supernatants were pooled together, diluted  
179 with 2.5 mL MilliQ water and filtered using a syringe through a 0.45 µm pore size filter. The  
180 filtrate was applied to an ODS cartridge (Waters, Missisagua, Ontario, Canada) preactivated  
181 with methanol following manufacturer's instructions. The cartridge was washed with 1 mL  
182 30% methanol (v/v) and lenthionine was eluted with 1 mL 65% methanol (v/v). Obtained  
183 eluate (50 µL) was injected into an HPLC-DAD system (the same column and equipment  
184 than above described) and developed using an isocratic mobile phase (65% methanol v/v), a  
185 constant flow (0.7 mL/min) and temperature (45 °C). Lenthionine (retention time 10.4 min)  
186 was quantified at 230 nm and identified using a lenthionine commercial standard.

#### 187 ***Ergosterol determination by GC-MS-FID***

188 Fungal sterols from samples were evaluated following the procedure described by  
189 Gil-Ramirez *et al.* (2013).<sup>21</sup> The unsaponified fractions obtained (6 mg/mL) were injected  
190 into an Agilent HP-5ms capillary column (30 m x 0.25 mm i.d. and 0.25 µm phase thickness).  
191 The column was connected to a 7890A System gas chromatograph (Agilent Technologies,  
192 Santa Clara, CA, USA), comprising a split/splitless injector, an electronic pressure control, a  
193 G4513A autoinjector, a 5975C triple-axis mass spectrometer detector and a GC-MS Solution  
194 software. The injector and detector conditions as well as the column temperature program

195 were those described by Gil-Ramirez *et al.* (2013).<sup>21</sup> Ergosterol was used as standard and  
196 hexadecane (10% v/v) as internal standard for quantification.

### 197 ***Antioxidant activities***

198 Mushroom powder and obtained extracts were dissolved in water (0.02 to 0.5 mg/mL)  
199 and assayed for their ABTS<sup>•+</sup> scavenging activity assay. ABTS radical was chemically  
200 generated using potassium persulfate and ABTS<sup>•+</sup> scavenging activity was analyzed  
201 spectrophotometrically according to Re *et al.* (1999),<sup>27</sup> measuring changes in absorbance  
202 (734 nm) at several concentrations after 15 minutes of incubation at room temperature in  
203 darkness. Similarly, samples were also dissolved in methanol (0.02 to 0.5 mg/mL) and mixed  
204 with DPPH<sup>•</sup> (76 µM) to determine their scavenging capacity according to Mau *et al.* (2001)  
205 <sup>28</sup>. Absorbance at 517 nm was recorded at several concentrations after 15 min incubation at  
206 room temperature in darkness. For both radicals the IC<sub>50</sub> was established using the linear  
207 correlation obtained with increasing sample concentrations and compared with Trolox to  
208 express the results as their TEAC values (trolox equivalent antioxidant capacity).

209 The ferric ion reducing power of the extracts was evaluated according to the method  
210 of Oyaizu (1986)<sup>29</sup>. Samples were dissolved in 200 mM sodium phosphate buffer (0.1 to 10  
211 mg/mL) and treated as described by Mau *et al.* (2005)<sup>30</sup>. Absorbance increase was recorded  
212 at 700 nm using several concentrations to estimate their EC<sub>50</sub>. Afterwards, it was expressed  
213 as TEAC values to be able to compare with the other antioxidant activities.

### 214 ***HMGCR inhibitory activity***

215 The obtained extracts were solubilized in water, ethanol:water (1:4) or assay buffer  
216 (50 mg/mL) and applied (20 µL) into a 96-wells plate. Their inhibitory activity was measured  
217 using the commercial HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) activity

218 assay (Sigma-Aldrich, Madrid, Spain) according to the manufacturer's instructions by  
219 monitoring their absorbance change (340 nm) at 37 °C using a 96-wells microplate reader  
220 BioTek Sinergy HT (BioTek, Winooski, USA). Pravastatin was utilized as a control for  
221 positive inhibition.

### 222 *ACE inhibitory activity*

223 The Angiotensin-I Converting Enzyme (ACE) inhibitory activity of the obtained  
224 extracts was evaluated using the fluorimetric method described by Sentandreu & Toldra  
225 (2006)<sup>31</sup> with slight modifications. Basically, 40 µL of different samples dilutions were added  
226 to a 96-wells plate, followed by addition of 160 µL of Abz-Gly-Phe(NO<sub>2</sub>)-Pro (0.45 mM)  
227 and 40 µL of ACE working solution (0.04 U/mL). The plate was incubated during 1 h at 37  
228 °C measuring the generated fluorescence with excitation and emission wavelengths  
229 respectively 355 and 405 nm. Milli Q water was utilized as a control for negative inhibition.

### 230 *Statistical analysis*

231 Differences were evaluated at a 95 % confidence level ( $p \leq 0.05$ ) using a one-way analysis  
232 of variance (ANOVA) followed by Tukey's Multiple Comparison test. Statistical analysis  
233 was performed using GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA,  
234 USA). Correlation between different variables was evaluated by computing Pearson  
235 correlation coefficient and determination coefficient ( $p \leq 0.05$ ).

## 236 **Results and discussion**

### 237 *Selection of the starting material*

238 The distribution of compounds with beneficial activities against CVDs within the  
239 *Lentinula edodes* fruiting body was investigated as a preliminary study to elucidate whether  
240 it was more convenient to use the complete mushroom or perhaps only caps or stipes as raw

241 material for the extractions. However, when the amount of the main bioactive compounds  
242 was determined (Table 1), no significant differences were noticed between tissues. They  
243 contained approx. 40 % (w/w) carbohydrates and most of them were  $\beta$ -glucans since chitins  
244 were found in lower concentrations. Ergosterol and the other bioactive compounds showed  
245 levels similar to previous studies<sup>16,25,32</sup> being lenthionine the compound found in the lowest  
246 concentration (0.15 mg/g) but also similar to other publications.<sup>13,26</sup>

247         The lower part of *L. edodes* stipes (the one is in contact with the cultivation substrate)  
248 is considered as a by-product and it is usually discarded during harvesting and not  
249 commercialized. However, the stipes showed similar concentrations than the complete  
250 fruiting body not only of the bioactive molecules but also of other nutrients such as proteins  
251 or carbohydrates. This observation indicated that the wasted stipes could be used as source  
252 of bioactive compounds as well as the complete fruiting bodies being an alternative for  
253 valorization of these wastes. Nevertheless, since the fruiting bodies were more easily  
254 available in larger concentrations the following experiments were carried out using the  
255 complete mushrooms.

### 256 *Sequential extraction yields*

257         The sequential extraction method was designed to optimize the use of shiitake  
258 mushrooms or their by-products (as they showed similar composition) as material to extract  
259 bioactive compounds. The idea was to consecutively use the residue of one extraction to carry  
260 out the next one in order to maximize the number of compounds that could be selectively  
261 isolated in each step avoiding the use of larger amounts of mushroom powder for independent  
262 extractions.

263         Water extraction (at room temperature) was selected as first extraction step because  
264 some of the bioactive compounds that could be solubilized in this medium were not

265 thermostable (see later for details). Then, the lipid fraction could be extracted with SFE using  
266 moderate temperatures (as second step) and in the third step hot water could be used to extract  
267 heat resistant molecules such as dietary fibers improving the intestinal bioavailability (for  
268 specific  $\beta$ -glucans) and making them more accessible for colonic microbiota.<sup>33,34</sup>

269         With the first extraction, water extracted 37 g from 100 g (w/w) of the mushroom  
270 powder (Figure 2). This method was previously used to obtain water-soluble  
271 polysaccharides<sup>35</sup> and other compounds of lower molecular weight.<sup>36</sup> The lowest yield (1.1  
272 %) was obtained with supercritical CO<sub>2</sub> extraction of the generated residue (1.7% of ReA)  
273 since it mostly extracted lipophilic compounds (ExB) and mushrooms have a low lipid  
274 content. Moreover, supercritical CO<sub>2</sub> exhibit a high selectivity enabling high recoveries of  
275 specific fatty acids, sterols and derivatives from fungal or other matrices.<sup>37</sup> Nevertheless, the  
276 obtained yield was similar to those described in previous publications where SFE extractions  
277 were carried out directly from fruiting bodies<sup>38,39</sup> indicating that SFE extractions could be  
278 also carried out using the residues obtained after the first extraction step. The last step, a hot  
279 water extraction (98 °C), generated a fraction (ExC) containing 20 % (w/w) of ReB (12 % of  
280 the initial mushroom powder) leaving still a large insoluble fraction (ReC) encompassing  
281 49.5% of the starting material. This procedure is usually utilized to extract certain  
282 polysaccharides from the rest of non-soluble dietary fibres that remain in the residual  
283 fraction.<sup>40,41</sup>

#### 284 *Distribution of bioactive compounds within the obtained fractions*

285         The levels of the different fungal polysaccharides were evaluated in all the obtained  
286 fractions. Results indicated that the water insoluble fractions contained higher levels of total  
287 carbohydrates,  $\beta$ -glucans and chitins than water-soluble or SFE fractions (Figure 3a). The  
288 mushroom powder contained 40.7 % (w/w) total carbohydrates where 29.3 % of them were

289  $\beta$ -glucans and 6.0 % chitins suggesting that the remaining low percentage (approx. 5 %)   
290 should include oligosaccharides, sugars and perhaps small amounts of  $\alpha$ -glucans or other   
291 heterosaccharides. Total carbohydrates values were in concordance with the literature.<sup>42</sup>  $\beta$ -   
292 glucans and chitins were slightly higher than some reports<sup>43,44</sup> but in the same range than   
293 others.<sup>45,46,47</sup> Differences might be due to the different methodologies utilized for their   
294 determination.

295         The water extract (ExA) contained a lower content of total carbohydrates and more   
296 than half of them were probably sugars and oligomers since they are easily solubilized in   
297 water and their  $\beta$ -glucan content was also lower than in the mushroom powder (10.8 %).   
298 Although in low amounts, chitins were also detected but they might be degradation products   
299 or low molecular weight derivatives from chitins since the latter compounds are completely   
300 insoluble in water. These derivatives were also noticed in other reports<sup>17,20</sup> and they might be   
301 involved, together with the water soluble  $\beta$ -glucans, in the interesting biological activities   
302 noticed in mushroom water extracts. Water soluble  $\beta$ -glucans,  $\alpha$ -glucans and   
303 fucomannogalactans were pointed as compounds potentially involved in the HMG-CoA   
304 reductase inhibitory activity noticed *in vitro* for water soluble extracts.<sup>36</sup> Moreover, chitin   
305 oligomers (water-soluble low molecular weight chitin (LMWC) and chitooligosaccharides   
306 (COs) derivatives) could be involved in the hypocholesterolemic properties noticed for these   
307 extracts.<sup>48</sup>

308         ReA and ReB showed a very similar carbohydrates profile including approx. 39-40%   
309  $\beta$ -glucans and 7-8% chitins indicating that the supercritical CO<sub>2</sub> extraction did not   
310 significantly influenced the polysaccharide composition of the residue obtained after water   
311 extraction and none of them was extracted.

312         Alkaline/acid or hot water extractions are usually required to achieve fractions with   
313 high polysaccharides yields.<sup>35</sup> The hot water extraction did not succeed to separate  $\beta$ -glucans

314 from chitins. The  $\beta$ -glucans extracted with hot water accounted for approx. less than half of  
315 the total carbohydrates noticed in ExC. As probably most of the oligosaccharides and  
316 monosaccharides were previously extracted in the ExA, the rest of carbohydrate content  
317 could be due to  $\alpha$ -glucans or other heteropolysaccharides characteristic from *L. edodes* that  
318 were also extracted. Shiitake  $\beta$ -glucans such as lentinan, are usually isolated using hot water  
319 extractions although their yields could be enhanced if alkaline media are used. However,  
320 alkalis were not recommended since they interfere with the lentinan 3D structure, essential  
321 for its biological activities.<sup>49</sup> Hot water soluble polysaccharides were suggested to decrease  
322 the oxidative damage related to hypercholesterolemia and modulating immune system.<sup>50-52</sup>

323 Furthermore, approx. 2/3 of the carbohydrates present in the residue ReC were  $\beta$ -  
324 glucans, and chitins (10.2 % w/w) that remained being part of the insoluble fractions. They  
325 were not extracted neither with cold/hot water or supercritical CO<sub>2</sub> since their concentrations  
326 in all the analyzed residues were almost the same. Their complex-forming capacity and  
327 polymeric structure are responsible for their extremely low solubility in many simple  
328 solvents.<sup>53</sup> However, this characteristic confers them the ability to act as dietary fibres  
329 remaining undigested in the intestine and acting on the colonic flora as prebiotic or as  
330 hypocholesterolemic fibers.<sup>48,54</sup>

331 The total protein content measured in shiitake mushroom was in the range of  
332 previously reported studies since they might change from approx. 13 to 23 % depending on  
333 the cultivation conditions, developmental stage or commercial strain.<sup>55-57</sup> The highest protein  
334 content (Figure 3a) was obtained in ExA, indicating that a considerable amount of Shiitake  
335 proteins might be easily extracted with cold water, probably because free proteins, peptides  
336 and amino acid derivatives are included in this fraction. Indeed, in this fraction higher  
337 amounts of small proteins and peptides (8.57 mg/g) (with molecular weight (MW) between  
338 10 and 3 kDa) than larger proteins (5.88 mg/g) (MW > 10 kDa) were noticed. It also

339 contained a low amount of peptides and N-containing compounds with MW < 3kDa (0.83  
340 mg/g). But, proteins might be also bound to polysaccharides as glycoproteins or  
341 proteoglycans impairing their extraction therefore, other proteins were found in the residues.  
342 The high pressure (and/or mild temperature) utilized during SFE extraction seemed to  
343 partially denature proteins since ReB protein levels were not the sum of those noticed in the  
344 fractions from the following extraction step (Table 2). Nevertheless, the ExC obtained still  
345 contained high protein levels and only low amounts remained in ReC (Figure 3a) suggesting  
346 that hot water enhanced extraction of many more proteins or different ones from those found  
347 in ExA. Nevertheless, the temperature selected might have also influenced proteins structure  
348 generating breaking down products from large (5.4 mg/g MW>10 kDa) and smaller proteins  
349 particularly those with MW between 10 to 3 kDa since the ExC contained lower content (1.84  
350 mg/g) than ExA and the fraction with lower MW contained more peptides (1.74 mg/g MW  
351 <3 kDa).

352 Eritadenine is a water-soluble alkaloid therefore it was mainly extracted with cold  
353 water when compared with the amount noticed in the mushroom powder (Table 2). The  
354 minimal amount that remained in the residues was then almost completely extracted with hot  
355 water. These results also suggested that eritadenine was resistant to high temperatures and its  
356 extraction yield could be enhanced by increasing the extraction temperature. Eritadenine was  
357 2.2 folds more concentrated in the ExA than in the shiitake powder (Figure 3b), amounts that  
358 were only slightly lower than those described in other studies obtained with more complex  
359 extraction procedures.<sup>25,58</sup>

360 Lenthionine was detected in shiitake powder at similar levels than previously reported  
361 .<sup>13,26</sup> It was also noticed in higher concentrations in the ExA extracts (Figure 3b). Afterwards,  
362 only traces remained in ReA but probably the slight increase of temperature together with  
363 the high pressure utilized for SFE extraction was sufficient to degrade it being undetected in

364 the following extracted fractions. Lenthionine levels were drastically reduced when  
365 extraction temperature was higher than 80 °C.<sup>59,60</sup> Thus, apparently pressurized extractions  
366 made the compound more susceptible to degradation.

367 Ergosterol was mainly extracted with SFE (Table 2) obtaining a highly concentrated  
368 ExB extract (88.7 mg/g) (Figure 3c). This result was not surprising since previous works  
369 indicated that this lipophilic constituent that can be easily extracted with supercritical  
370 CO<sub>2</sub>.<sup>21,61,62</sup> Ergosterol in ExB represented 72 % of total sterols since the extract also included  
371 other derivatives such as ergosta-7,22-dienol (18.5 mg/g), fungisterol (15.3 mg/g) and  
372 ergosta-5,7-dienol (1.5 mg/g). The supercritical extraction was carried out using steel spheres  
373 instead of sand as carrier material to facilitate the subsequent ReB separation for further  
374 processing however, ergosterol yields were only slightly lower than usually obtained in  
375 similar extractions using sea sand (8.9 and 11.8 % repectively).

376 Total phenolic compounds were mostly found in the water extracts. Obtained  
377 fractions (ExA and ExC) contained respect. 3.0 and 2.5 fold more phenols than initially  
378 detected in the mushroom powder. The second water extraction complemented the first one  
379 leaving in the last residue a very low amount of these compounds (Figure 3c). These results  
380 were in concordance with previous studies reporting that water achieved higher recoveries of  
381 total phenolic compounds in comparison with organic solvents such as methanol.<sup>16</sup>

### 382 ***Biological activities of the obtained fractions***

383 The antioxidant activity of the obtained fractions was evaluated as their ABTS<sup>•+</sup> and  
384 DPPH<sup>•</sup> scavenging capacities and as their ferric ion reducing power. Results indicated that  
385 those fractions containing high concentrations of proteins, eritadenine and phenolic  
386 compounds showed high antioxidant activities (Figure 4). Their levels were more than double  
387 of the initial mushroom powder. ExA and ExC were the fractions with the lowest IC<sub>50</sub> values

388 (respectively 0.05 and 0.06 mg/mL when using ABTS<sup>•+</sup> and 0.15 and 0.17 mg/mL when  
389 using DPPH<sup>•</sup>) and the lowest EC<sub>50</sub> for their reducing powder (0.26 and 0.28 mg/mL).  
390 According to their TEAC values, the obtained extracts and residues showed higher affinity  
391 for the ABTS<sup>•+</sup> radical than for DPPH<sup>•</sup>. The use of different solvents might also influence the  
392 obtained results since less polar compounds were extracted when methanol was used to carry  
393 out the DPPH<sup>•</sup> assay. The shiitake and ExA antioxidant activities were in concordance with  
394 previous studies<sup>16, 63</sup> where it was indicated that their antioxidant activities as radical  
395 scavengers were mainly due to the phenolic content and ergothioneine.<sup>14</sup> Similarly, the  
396 antioxidant activities noticed in the extracts also showed high correlations with their phenolic  
397 concentration (with R<sup>2</sup> = 0.99 for ABTS<sup>•+</sup> and reducing power assays and 0.97 for DPPH<sup>•</sup>  
398 assays).

399 Cholesterol lowering in serum can be achieved via several mechanisms but mainly by  
400 impairing of exogenous cholesterol absorption or inhibiting endogenous cholesterol  
401 biosynthesis. The hypocholesterolemic activity of the obtained fractions was evaluated as  
402 their ability to inhibit the key enzyme of the cholesterol biosynthetic pathway (HMGCR)  
403 since the capacity to impair cholesterol absorption was already evaluated elsewhere for  
404 similar extracts containing high ergosterol levels (as ExB) and high β-glucans and dietary  
405 fibers contents (as respect. ExC and ReC).<sup>7,17</sup> The initial shiikate powder showed a  
406 remarkable HMGCR inhibitory activity acting as pravastatin used as control (Figure 5). ExA  
407 showed similar inhibitory activity (98 %) than the mushroom indicating that the responsible  
408 compounds might be water soluble. However, the inhibitors were not completely separated  
409 with a single cold water extraction since ReA and ReB were still able to lower HMGCR  
410 activity (respectively 86 and 80 %). Perhaps, to further improve the extraction yield of  
411 HMGCR inhibitors serial extractions with cold water could be carried out although this might  
412 involve dilution of the other bioactive compounds. Increase of the water temperature for

413 extraction is not encouraged because after heat application, the inhibitory activity of the  
414 obtained fractions was drastically reduced to 31 and 24 % for respect. ExC and ReC,  
415 suggesting that the compounds responsible for the inhibition were thermolabile. This  
416 indication was also noticed in previous studies.<sup>33</sup> The ExB extract was also able to inhibit 59  
417 % of the enzyme activity indicating that perhaps other compounds soluble in supercritical  
418 CO<sub>2</sub> (more lipophilic molecules) were also interfering with the HMGCR activity as was also  
419 previously noticed by Gil-Ramirez *et al.* (2013)<sup>64</sup> for SFE extracts obtained from *Agaricus*  
420 *bisporus*.

421         The hypotensive activity of the obtained fractions was evaluated as their capacity to  
422 inhibit the angiotensin converting enzyme. However, since it was previously reported that  
423 certain peptides were responsible compounds a more detailed study was carried out on the  
424 two extracts including larger amounts of proteins (ExA and ExC) by dividing them in 3  
425 fractions of different molecular weights. The protein contents of fractions obtained from ExA  
426 were higher than those from ExC and within the fractions, lower molecular weight fractions  
427 contained less proteins, peptides and other N-containing compounds (Table 3). Fractions <10  
428 kDa showed higher IC<sub>50</sub> than higher MW fractions ranging from 0.45 mg/mL for the MW>10  
429 kDa fraction from ExA up to 1.63 mg/mL for the MW<3 kDa fraction from ExC. These  
430 values were lower than those reported in similar studies where other mushrooms such as  
431 *Hypsizygus marmoreus* (6.4 mg/mL)<sup>11</sup> or mycelia extracts from *Lactarius camphorates* (1.6  
432 mg/mL)<sup>12</sup> were analyzed. A significant correlation between protein content and ACE  
433 inhibitory activity was found however, when IC<sub>50</sub> values were expressed taking into account  
434 the amount of proteins detected, fractions with lower molecular weight displayed the largest  
435 inhibitory capacity. Therefore, these results were in concordance with previous studies  
436 carried out on close related species such as *Lentinula polychrous* where small peptides were  
437 pointed as responsible compounds of their hypotensive properties.<sup>65</sup>

438

## Conclusions

439           The present study showed that bioactive compounds can be differentially extracted  
440 from *Lentinula edodes* fruiting bodies or by-products using a sequential extraction method.  
441 Extracts obtained with cold water (ExA) contained high levels of water soluble  $\beta$ -glucans,  
442 chitooligosaccharides and other carbohydrates that were pointed as potential responsible for  
443 the high HMGCR inhibitory activity showed in this extract. It also contained eritadenine with  
444 cholesterol lowering properties, lenthionine that can inhibit platelet aggregation, peptides  
445 with ACE inhibitory capacity and antioxidant phenols. Then, the residue after this extraction  
446 can be submitted to supercritical CO<sub>2</sub> extraction to obtain a fungal sterol-enriched fraction  
447 (ExB) with the ability of displacing cholesterol from dietary mixed micelles formed after  
448 digestion impairing its absorption. Afterwards, the remaining material can be submitted to  
449 hot water extraction yielding an extract (ExC) containing  $\beta$ -glucans with bile acid-binding  
450 capacities (able to interfere cholesterol absorption) and similar solubility than lentinan and a  
451 residue (ReC) including dietary fibres such as  $\beta$ -glucans and chitins that apparently,  
452 according to previous studies, modulate human microbiota reducing the risk of CVDs.  
453 Therefore, many biologically active compounds can be separated within different fractions  
454 from the same batch of shiitake mushrooms if the described methods are sequentially applied.  
455 Then, the obtained fractions will contain higher concentrations of the bioactive compounds  
456 than the mushroom itself and they will be transformed into more bioaccessible forms (*i.e.*  
457 dietary fibers will be more easily fermented by colonic microbiota activating  
458 hypocholesterolemic mechanisms or absorbed by M cells in the intestine).

459

## Acknowledgements

460 The research was supported by AGL2014-56211 national R+D program from the Spanish  
461 Ministry of Science and Innovation and S2013/ABI-2728 regional program from the  
462 Community of Madrid (Spain).

463 **Conflict of interest:** None.

464 **Notation**

465 ACE = Angiotensin-I Converting Enzyme

466 CVD = Cardiovascular disease

467 HMGCR = 3-hydroxy-3-methylglutaryl coenzyme A reductase

468 SFE = Supercritical fluid extraction

469 TEAC = Trolox equivalent antioxidant capacity

**Literature cited**

1. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, Despres JP. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. *Arch. Intern. Med.* 2001;161:2685-2692.

2. Seo HS, Choi MH. Cholesterol homeostasis in cardiovascular disease and recent advances in measuring cholesterol signatures. *J. Steroid Biochem. Mol. Biol.* 2015;153:72-79.
3. Iwaniak A, Minkiewicz P, Darewicz M. Food-originating ACE inhibitors, including antihypertensive peptides, as preventive food components in blood pressure reduction. *Comp. Rev. Food Sci. Food Saf.* 2014;13:114-124.
4. Gil-Ramirez A, Soler-Rivas C. The use of edible mushroom extracts as bioactive ingredients to design novel functional foods with hypocholesterolemic activities. In: Pesti G. *Mushrooms: Cultivation, Antioxidant Properties and Health Benefits*. New York: Nova Science Publishers, 2014:43-73.
5. Chen J, Huang XF. The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. *J. Clin. Lipidol.* 2009;3:154-158.
6. Gallaher DD, Gallaher CM, Mahrt GJ, Carr TP, Hollingshead CH, Hesslink Jr R, Wise J. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. *J. Am. Coll. Nutr.* 2002;21:428-433.
7. Gil-Ramirez A, Ruiz-Rodriguez A, Marin FR, Reglero G, Soler-Rivas C. Effect of ergosterol-enriched extracts obtained from *Agaricus bisporus* on cholesterol absorption using an *in vitro* digestion model. *J. Funct. Foods.* 2014;11:589-597.
8. Shimada Y, Morita T, Sugiyama K. Eritadenine-induced alterations of plasma lipoprotein lipid concentrations and phosphatidylcholine molecular species profile in rats fed cholesterol-free and cholesterol-enriched diets. *Biosci. Biotechnol. Biochem.* 2003;67:996-1006.

9. Sugiyama K, Akachi T, Yamakawa A. Hypocholesterolemic action of eritadenine is mediated by a modification of hepatic phospholipid metabolism in rats. *J. Nutr.* 1995;125:2134-2144.
10. Caz V, Gil-Ramirez A, Santamaria M, Tabernero M, Soler-Rivas C, Martin-Hernandez R, Marin FR, Reglero G, Largo C. Plasma cholesterol-lowering activity of lard functionalized with mushroom extracts is independent of Niemann-Pick C1-like 1 protein and ABC sterol transporters gene expression in hypercholesterolemic mice. *J. Agric. Food Chem.* 2016;64:1686-1694.
11. Kang MG, Kim YH, Bolormaa Z, Kim MK, Seo GS, Lee JS. Characterization of an antihypertensive Angiotensin I-Converting Enzyme inhibitory peptide from the edible mushroom *Hypsizygus marmoreus*. [published online, 2013]. *Biomed. Res. Int.* doi: 10.1155/2013/283964.
12. Yao PS, Gao XJ. Inhibitory activity of extracts from mycelia materials of several mushrooms on the Angiotensin I-Converting Enzyme. *Adv. Mat. Res.* 2013;610-613:3541-3544.
13. Shimada S, Komamura K, Kumagai H, Sakurai H. Inhibitory activity of shiitake flavor against platelet aggregation. *Biofactor.* 2004;22:177-179.
14. Dubost NJ, Ou B, Beelman RB. Quantification of polyphenols and ergothioneine in cultivated mushrooms and correlation to total antioxidant capacity. *Food Chem.* 2007;105:727-735.
15. Hu H, Zhang Z, Lei Z, Yang Y, Sugira N. Comparative study of antioxidant activity and antiproliferative effect of hot water and ethanol extracts from the mushroom *Inonotu obliquus*. *J. Biosci. Bioeng.* 2009;107:42-48.

16. Ramirez-Anguiano AC, Santoyo S, Reglero G, Soler-Rivas C. Radical scavenging activities, endogenous oxidative enzymes and total phenols in edible mushrooms commonly consumed in Europe. *J. Sci. Food Agric.* 2007;87:2272-2278.
17. Palanisamy M, Aldars-Garcia L, Gil-Ramirez A, Ruiz-Rodriguez A, Marin FR, Reglero G, Soler-Rivas C. Pressurized water extraction of  $\beta$ -glucan enriched fractions with bile acids-binding capacities obtained from edible mushrooms. *Biotechnol. Prog.* 2014;30:319-400.
18. Smiderle FR; Morales D, Gil-Ramirez A, de Jesus LI, Gilbert-Lopez B, Iacomini M, Soler-Rivas C. Evaluation of microwave-assisted and pressurized liquid extractions to obtain  $\beta$ -D-glucans from mushrooms. *Carbohydr. Polym.* 2017;156: 165-174.
19. Alzorqi I, Singh A, Manickam S, Al-Qrimli HF. Optimization of ultrasound assisted extraction (UAE) of  $\beta$ -D-glucan polysaccharides from *Ganoderma lucidum* for prospective scale-up. *Res-Eff. Tech.* 2017; 3: 46-54.
20. Wu T; Zivanovic S, Draughon FA, Sams CE. Chitin and chitosan: value-added products from mushroom waste. *J. Agric. Food Chem.* 2004;52:7905-7910.
21. Gil-Ramirez A, Aldars-Garcia L, Palanisamy M, Jiverdeanu RM, Ruiz-Rodriguez A, Marin FR, Reglero G, Soler-Rivas C. Sterol enriched fractions obtained from *Agaricus bisporus* fruiting bodies and by-products by compressed fluid technologies (PLE and SFE). *Innov. Food Sci. Emerg. Technol.* 2013;18:101-107.
22. Garcia-Risco MR, Vicente G, Reglero G, Fornari T. Fractionation of thyme (*Thymus vulgaris L.*) by supercritical fluid extraction and chromatography. *J. Supercrit. Fluids.* 2011;55:949–954.
23. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. *Anal. Chem.* 1956;28:350-356.

24. Rementeria A, Ezkurra P, Hernando F, Ponton J, Sevilla MJ, Cisterna R. Chitin assay to estimate the growth of *Candida albicans* in organs of infected mice. *J. Med. Vet. Mycol.* 1991;29:15-23.
25. Afrin S, Rakib MA, Kim BH, Kim JO, Ha YL. Eritadenine from edible mushrooms inhibits activity of Angiotensin Converting Enzyme in Vitro. *J. Agric. Food Chem.* 2016;64:2263-2268.
26. Hiraide M, Kato A, Nakashima T. The smell and odorous components of dried shiitake mushroom, *Lentinula edodes* V: changes in lenthionine and lentinic acid contents during the drying process. *J. Wood Sci.* 2010;56:477-482.
27. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radic. Biol. Med.* 1999;26:1231-1237.
28. Mau JL, Chao GR, Wu KT. Antioxidant properties of methanolic extracts from several ear mushrooms. *J. Agric. Food Chem.* 2001;49:5461-5467
29. Oyaizu M. Studies on products of browning reactions: antioxidant activities of products of browning reaction prepared from glucosamine. *Jpn. J. Nutr.* 1986;44:307-315.
30. Mau J, Tsai S, Tseng Y, Huang S. Antioxidant properties of methanolic extracts from *Ganoderma tsugae*. *Food Chem.*;93:641-649.
31. Sentandreu MA, Toldrá F. A rapid, simple and sensitive fluorescence method for the assay of angiotensin-I converting enzyme. *Food Chem.* 2006;97:546-554.
32. Hammann S, Lehnert K, Vetter V. Esterified sterols and their contribution to the total sterols in edible mushrooms. *J. Food Compost. Anal.* 2016;54:48-54.
33. Gil-Ramirez A, Clavijo C, Palanisamy M, Ruiz-Rodriguez A, Navarro-Rubio M, Perez M, Marin FR, Reglero G, Soler-Rivas C. Screening of edible mushrooms and

- extraction by pressurized water (PWE) of 3-hydroxy-3-methyl-glutaryl CoA reductase inhibitors. *J. Funct. Foods*. 2013;5:244-250.
34. Savelkoul HFJ, Chanput W, Wichers HJ. Immunomodulatory effects of mushrooms  $\beta$ -glucans. In: Calder PP, Yaqoob P. Diet, Immunity and Inflammation. Sawston, United Kingdom: Woodhead Publishing, 2013:416-434.
  35. Ruthes AC, Smiderle FR, Iacomini M. D-glucans from edible mushrooms: a review on the extraction, purification and chemical characterization approaches. *Carbohydr. Polym.* 2015;117:753-761.
  36. Gil-Ramirez A, Caz V, Smiderle FR, Martin-Hernandez R, Largo C, Tabernero M, Marin FR, Iacomini M, Reglero G. Water soluble compounds from *Lentinula edodes* influencing the HMG-CoA reductase activity and the expression of genes involved in the cholesterol metabolism. *J. Agric. Food Chem.* 2016;64:1910-1920.
  37. Cheng SH, Yang FC, Yang YH, Hu CC, Chang WT. Measurements and modeling of the solubility of ergosterol in supercritical carbon dioxide. *J. Taiwan Inst. Chem. E.* 2013;44:19-26.
  38. Kitzberger CSG, Smania A, Pedrosa RC, Ferreira SRS. Antioxidant and antimicrobial activities of shiitake (*Lentinula edodes*) extracts obtained by organic solvents and supercritical fluids. *J. Food Eng.* 2007;80:631-638.
  39. Morales D, Gil-Ramirez A, Smiderle FR, Piris AJ, Ruiz-Rodriguez A, Soler-Rivas C. Vitamin D-enriched extracts obtained from shiitake mushrooms (*Lentinula edodes*) by supercritical fluid extraction and UV-irradiation. *Innov. Food Sci. Emerg. Technol.* 2017;41:330-336.
  40. Palacios I, Garcia-Lafuente A, Guillamon E, Villares A. Novel isolation of water-soluble polysaccharides from the fruiting bodies of *Pleurotus ostreatus* mushrooms. *Carbohydr. Res.* 2012;358:72-77.

41. Smiderle FR, Alquini G, Tadra-Sfeir MZ, Iacomini M, Wichers HJ, Van Griensven LJD. *Agaricus bisporus* and *Agaricus brasiliensis* (1→6)-β-D-glucans show immunostimulatory activity on human THP-1 derived macrophages. *Carbohydr. Polym.* 2013;94:91-99.
42. Grundemann C, Garcia-Kaufer M, Sauer B, Scheer R, Merdivan S, Bertin P, Huber R, Lindequist U. Comparative chemical and biological investigations of β-glucan-containing products from shiitake mushrooms. *J. Funct. Foods.* 2015;18:692-702.
43. Nitschke J, Altenbach HJ, Malolepszy T, Mölleken H. A new method for the quantification of chitin and chitosan in edible mushrooms. *Carbohydr. Res.* 2011; 346:1307-1310.
44. Sari M, Prange A, Lelley JI, Hambitzer R. Screening of beta-glucan contents in commercially cultivated and wild growing mushrooms. *Food Chem.* 2017;216:45-51.
45. Gil-Ramirez A, Clavijo C, Palanisamy M, Soler-Rivas C, Ruiz-Rodriguez A, Marin FR, Reglero G, Perez M. Edible mushrooms as potential sources of new hypocholesterolemic compounds. *Proceedings of 7<sup>th</sup> Conference on Mushroom Biology and Mushroom Product.*, 2011;2:110-119.
46. Vetter J. Chitin content of cultivated mushrooms *Agaricus bisporus*, *Pleurotus ostreatus* and *Lentinula edodes*. *Food Chem.* 2006;102:6-9.
47. Roncero-Ramos I, Mendiola-Lanao M, Perez-Clavijo, M, Delgado-Andrade C. Effect of different cooking methods on nutritional value and antioxidant activity of cultivated mushrooms. *Int. J. Food Sci. Nutr.* 2017;68:287-297.
48. Harish-Prashanth KV, Tharanathan RN. Chitin/chitosan: modifications and their unlimited application potential – an overview. *Trends Food Sci. Technol.* 2007;18: 117-131.

49. Mohd-Jamil NA, Rahmad N, Nor-Rashid NM, Mohd-Yusoff MHY, Shaharuddin NS, Mohd-Salleh N. LCMS-QTOF determination of lentinan-lile- $\beta$ -D-glucan content isolated by hot water and alkaline solution from tiger's milk mushroom, termite mushroom, and selected local market mushrooms. [published online, 2013]. *J. Mycol.* doi: 10/1155/2013/718963
50. Xu C, HaiYang Z, JianHong Z, Jing G. The pharmacological effect of polysaccharides from *Lentinus edodes* on the oxidative status and expression of VCAM-1mRNA of thoracic aorta endothelial cell in high-fat-diet rats. *Carbohydr. Polym.* 2008;74:445-450.
51. Zheng R, Jie S, Hanchuan D, Moucheng W. Characterization and immunomodulating activities of polysaccharide from *Lentinus edodes*. *Int. Immunopharmacol.* 2005;5:811-820.
52. Zhu M, Nie P, Liang Y, Wang B. Optimizing conditions of polysaccharide extraction from *Shiitake* mushroom using response surface methodology and its regulating lipid metabolism. *Carbohydr. Polym.* 2013;95:644-648.
53. Pillai CKS, Paul W, Sharma CP. Chitin and chitosan polymers: Chemistry, solubility and fiber formation. *Prog. Polym. Sci.* 2009;34:641-678.
54. Aida FMNA, Shuhaimi M, Yazid M, Maaruf AG. Mushrooms as a potential source of prebiotics: a review. *Trends Food Sci. Technol.* 2009;20:567-575.
55. Carneiro AAJ, Ferreira ICFR, Dueñas M, Barros L, da Silva R, Gomes E, Santos-Buelga C. Chemical composition and antioxidant activity of dried powder formulations of *Agaricus blazei* and *Lentinus edodes*. *Food Chem.* 2013;138:2168-2173.
56. Longvah T, Deosthale YG. Compositional and nutritional studies on edible wild mushroom from northeast India. *Food Chem.* 1998;63:331-334.

57. Ming J, Chen L, Hong H, Li J. Effect of superfine grinding on the physico-chemical, morphological and thermogravimetric properties of *Lentinus edodes* mushroom powders. *J. Sci. Food Agric.* 2014;95:2431-2437.
58. Enman J, Rova U, Berglund KA. Quantification of the bioactive compound eritadenine in selected strains of shiitake mushroom (*Lentinus edodes*). *J. Agric. Food Chem.* 2007;55:1177-1180.
59. Shiga H, Yoshii H, Ohe H, Yasuda M, Furuta T, Kuwahara H, Ohkawara M, Linko P. Encapsulation of shiitake (*Lenthinus edodes*) flavors by spray drying. *Biosci. Biotechnol. Biochem.* 2003;68:66-71.
60. Wang H, Zhang M, Adhikari B. Drying of shiitake mushroom by combining freeze-drying and mid-infrared radiation. *Food Bioprod. Process.* 2015;94:507-517.
61. Mazzutti S, Ferreira SRS, Riehl CAS, Smania Jr A, Smania FA, Martinez J. Supercritical fluid extraction of *Agaricus brasiliensis*: Antioxidant and antimicrobial activities. *J. Supercrit. Fluids.* 2012;70:48–56.
62. Kitzberger CSG, Lomonaco RH, Michielin EMZ, Danielski L, Correia J, Ferreira SRS. Supercritical fluid extraction of shiitake oil: Curve modeling and extract composition. *J. Food Eng.* 2009;90:35–43.
63. Wu XJ, Hansen C. Antioxidant capacity, phenolic content, and polysaccharide content of *Lentinus edodes* grown in whey permeate-based submerged culture. *J. Food Sci.* 2008;73:M1-M8.
64. Gil-Ramirez A, Clavijo C, Palanisamy M, Ruiz-Rodriguez A, Navarro-Rubio M, Perez M, Marin FR, Reglero G, Soler-Rivas, C. Study on the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitory properties of *Agaricus bisporus* and extraction of bioactive fractions using pressurized solvent technologies (ASE and SFE). *J. Sci. Food Agric.* 2013;93:2789-2796.

65. Kokram T, Khammuang S, Sarnthima R. Angiotensin-I converting enzyme inhibitory activity of mushroom *Lentinus polychrous* Lév. and its development of healthy drink recipes. *Biocatal. Agric. Biotechnol.* 2016;8:121-125.

Table 1. Total carbohydrates (TC),  $\beta$ -glucans ( $\beta$ G), chitins (CH), total proteins (PR), eritadenine (EA), lenthionine (LT), ergosterol (ER) and total phenolic compounds (PH) levels of shiitake fruiting bodies and two separated tissues (indicated values are w/w).

	<b>TC</b> (g/100g)	<b><math>\beta</math>G</b> (g/100g)	<b>CH</b> (g/100g)	<b>PR</b> (g/100g)	<b>EA</b> (mg/g)	<b>LT</b> (mg/g)	<b>ER</b> (mg/g)	<b>PH</b> (mg/g)
<b>Whole</b>	40.67±0.65	29.32±1.04	6.03±0.29	13.42±0.22	1.43±0.13	0.15±0.01	2.40±0.02	9.27±0.05
<b>Cap</b>	39.72±2.42	29.89±1.55	5.96±0.87	13.81±0.12	1.13±0.01	0.13±0.01	2.24±0.04	9.68±0.50
<b>Stipe</b>	42.37±1.42	32.01±1.72	6.28±1.09	12.90±0.08	1.12±0.11	0.11±0.01	2.32±0.05	8.95±0.43

No significant differences ( $P \leq 0.05$ ) were found between different samples for the same component.

Table 2: Distribution of bioactive compounds within the obtained fractions expressed as percentage of initial dry mushroom powder (taking into consideration the obtained yields).

	<b>TC</b>	<b>βG</b>	<b>CH</b>	<b>PR</b>	<b>EA</b>	<b>LT</b>	<b>ER</b>	<b>PH</b>
	(g/100 g)	(g/100 g)	(g/100 g)	(g/100g SP)	(mg/g)	(mg/g)	(mg/g)	(mg/g)
<b>SP</b>	40.67±0.34 <sup>a</sup>	29.32±1.04 <sup>a</sup>	6.03±0.29 <sup>a</sup>	13.42±0.22 <sup>a</sup>	1.43±0.13 <sup>a</sup>	0.15±0.01 <sup>a</sup>	2.40±0.02 <sup>a</sup>	9.27±0.05 <sup>b</sup>
<b>ExA</b>	11.46±0.37 <sup>d</sup>	5.10±0.09 <sup>d</sup>	1.58±0.08 <sup>d</sup>	5.86±0.49 <sup>b</sup>	1.46±0.14 <sup>a</sup>	0.09±0.01 <sup>b</sup>	0.03±0.01 <sup>e</sup>	10.35±0.01 <sup>a</sup>
<b>ReA</b>	33.84±1.80 <sup>b</sup>	20.32±0.73 <sup>b</sup>	4.11±0.26 <sup>b</sup>	4.53±0.01 <sup>c</sup>	0.32±0.01 <sup>bc</sup>	0.01±0.01 <sup>c</sup>	2.12±0.11 <sup>b</sup>	4.84±0.20 <sup>c</sup>
<b>ExB</b>	n.d. <sup>e</sup>	n.d. <sup>f</sup>	n.d. <sup>f</sup>	n.d. <sup>e</sup>	n.d. <sup>c</sup>	n.d. <sup>c</sup>	0.79±0.01 <sup>d</sup>	0.04±0.00 <sup>e</sup>
<b>ReB</b>	34.07±0.94 <sup>b</sup>	21.17±0.24 <sup>b</sup>	3.66±0.10 <sup>b</sup>	4.36±0.04 <sup>c</sup>	0.41±0.03 <sup>bc</sup>	n.d. <sup>c</sup>	1.08±0.01 <sup>c</sup>	4.33±0.10 <sup>c</sup>
<b>ExC</b>	9.06±0.31 <sup>d</sup>	3.53±0.65 <sup>e</sup>	0.86±0.03 <sup>e</sup>	1.63±0.01 <sup>d</sup>	0.57±0.03 <sup>b</sup>	n.d. <sup>c</sup>	0.06±0.01 <sup>e</sup>	2.91±0.01 <sup>d</sup>
<b>ReC</b>	22.14±1.05 <sup>c</sup>	14.38±0.15 <sup>c</sup>	2.29±0.06 <sup>c</sup>	2.00±0.04 <sup>d</sup>	0.17±0.00 <sup>c</sup>	n.d. <sup>c</sup>	1.01±0.11 <sup>cd</sup>	2.85±0.33 <sup>d</sup>

n.d. = not detected

<sup>a-f</sup>Different letters denote significant differences ( $P \leq 0.05$ ) between different samples for the same component.

Table 3: Total protein content (PR) and ACE inhibitory activity (IC<sub>50</sub>) of the different molecular weight fractions obtained from ExA and ExC.

<b>Extract</b>	<b>Fraction</b>	<b>PR (mg/g fraction)</b>	<b>IC<sub>50</sub> (mg fraction/mL)</b>	<b>IC<sub>50</sub> /PR (mg protein/mL)</b>
ExA	MW >10 kDa	391.93±2.28 <sup>a</sup>	0.45±0.01 <sup>c</sup>	0.18±0.03 <sup>ab</sup>
	10 > MW > 3 kDa	237.97±3.34 <sup>b</sup>	0.91±0.08 <sup>bc</sup>	0.22±0.02 <sup>a</sup>
	MW < 3 kDa	18.10±1.28 <sup>f</sup>	1.06±0.09 <sup>bc</sup>	0.02±0.00 <sup>c</sup>
ExC	MW >10 kDa	192.81±3.28 <sup>c</sup>	0.74±0.07 <sup>c</sup>	0.14±0.00 <sup>b</sup>
	10 > MW > 3 kDa	87.77±2.28 <sup>d</sup>	1.21±0.09 <sup>b</sup>	0.11±0.01 <sup>c</sup>
	MW < 3 kDa	35.49±1.09 <sup>e</sup>	1.63±0.15 <sup>a</sup>	0.06±0.00 <sup>c</sup>

<sup>a-f</sup>Different letters denote significant differences ( $P \leq 0.05$ ) between different samples for the same column.

Figure 1. Outline of the sequential extraction method utilized to obtain different extracts from shiitake mushrooms.

Figure 2. Extraction yields obtained after each step of the sequential extraction method expressed as percentage (w/w) referred to the initial amount of shiitake powder (SP). Different letters (a-f) showed statistical significance ( $P \leq 0.05$ ) between different extractions.

Figure 3. Distribution of bioactive compounds within the extracts obtained from shiitake powder expressed as concentrations within each fraction. Levels of a) total carbohydrates,  $\beta$ -glucans, chitins and proteins, b) eritadenine and lenthionine and c) ergosterol and total phenolic compounds. Different letters (a-f) showed statistical significance ( $P \leq 0.05$ ) between different samples for the same compound.

Figure 4: ABTS<sup>+</sup> and DPPH<sup>•</sup> scavenging capacity and ferric ion reducing power of shiitake powder and the fractions obtained after the sequential extraction method expressed as their TEAC value. Different letters (a-f) showed statistical significance ( $P \leq 0.05$ ) between different samples.

Figure 5: HMGCR inhibitory activity of shiitake powder and the fractions obtained after the sequential extraction method. Different letters (a-d) showed statistical significance ( $P \leq 0.05$ ) between different samples.

Figure 1:

***Lentinula edodes***

Dried powder

Water extraction  
Stirring 1 min  
+ centrifugation 7 min 7000 rpm 10 °C

**ExA**

+ lyophilization

**ReA**

+ lyophilization

Supercritical CO<sub>2</sub> extraction  
35 MPa 40 °C 3 h

**ExB**

**ReB**

Hot water extraction  
Stirring under reflux 1 h  
+ centrifugation 7 min 7000 rpm 10 °C

**ExC**

+ lyophilization

**ReC**

+ lyophilization




Figure 2:






Figure 3:

a)



b)



c)




Figure 4:




Figure 5:

